IONS Stock — Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. (IONS)

Updated October 16, 2026.

IONS is a Stock. Total return is 365.7% over the past 35.4 years.

Ionis Pharmaceuticals is a commercial-stage biotechnology company developing RNA-targeted medicines for rare genetic and neurological diseases, with approved treatments for spinal muscular atrophy, hereditary angioedema, and amyloidosis, alongside a pipeline of investigational drugs in Phase 2 and Phase 3 clinical trials. The company does not currently have an established distribution program. Ionis appeals to investors seeking exposure to biotechnology innovation and rare disease treatments, though as a development-focused biotech firm it prioritizes reinvestment in research and clinical programs over regular income generation.

IONS performance

Price and return data through 2026-10-16.

Total return is 365.7% over the past 35.4 years. Over the past year its total return — price change plus distributions reinvested — is -41.2%. Its deepest 1-year drawdown was 51.0%.

IONS key facts

Asset type

Stock

Asset class

Equity

Inception date

05/17/1991

Distribution frequency

Bi-Monthly

Last close

$42.94 (as of 2026-10-16)

Market cap

$7,135,954,787

Average volume

1655598.0

Dividend

$0.11

Beta

0.382

Payout ratio

0.0%

Forward P/E

90.9091

EPS

$-3.48

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IONS risks and drawbacks

The deepest 1-year drawdown on record here is 51.0%.

More on IONS

• All tickers starting with I

Tagged: Healthcare, Dividend.

Frequently asked questions